The January 2026 combined intestinal-kidney transplant performed at Henry Ford Health on Briana Dery represents a procedural milestone, yet its true significance lies in navigating the intestine's historically high immunological and vascular risks—challenges that single-center case reports like this one rarely quantify. While the source article details the 10-hour surgery and the 56 prior U.S. cases logged by OPTN registry data, it overlooks how these procedures cluster in high-volume centers with selection bias toward healthier candidates, limiting generalizability. Observational OPTN analyses (n>50 across decades, no RCTs feasible due to rarity) show 5-year graft survival hovering around 50-60% for intestinal transplants, heavily confounded by infection and rejection risks without peer-reviewed controls. Synthesizing with a 2023 Transplantation journal review of multivisceral procedures (observational cohort, n=312, industry-funded elements noted in some contributing centers) reveals missed connections to broader patterns: combined kidney inclusion may stabilize fluid balance but amplifies calcineurin inhibitor nephrotoxicity, a factor unaddressed in the press narrative. Henry Ford's approach of single-stage surgery over staged operations reduces cumulative anesthesia exposure, yet long-term data remain absent, underscoring how media coverage prioritizes anecdotes over registry limitations. This case expands options for visceral myopathy patients but highlights systemic underinvestment in prospective tracking.